As previously reported, Truist analyst Asthika Goonewardene downgraded TCR2 Therapeutics (TCRR) to Hold from Buy with a price target of $3, down from $8, after the company entered into a definitive merger agreement under which Adaptimmune (ADAP) will combine with TCR2 in an all-stock transaction. Truist would have liked to have seen TCR2 shares get a better premium in the swap, but thinks the deal provides a way to pivot to a cell therapy name that also embraces the T-cell Receptor, but is closer to commercialization, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TCRR:
- TCR2 Therapeutics downgraded to Hold from Buy at Truist
- TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Adaptimmune downgraded to Hold from Buy at JonesResearch
- Adaptimmune Craters after Acquiring TCRR
- Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors